Structure Therapeutics’ (GPCR) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note released on Monday,Benzinga reports. The firm currently has a $65.00 price objective on the stock.

GPCR has been the topic of a number of other reports. JMP Securities restated a “market outperform” rating and set a $89.00 target price on shares of Structure Therapeutics in a research report on Monday. William Blair started coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating on the stock. HC Wainwright cut their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Monday, May 12th. Finally, Citigroup started coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They set a “buy” rating and a $60.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $76.17.

Structure Therapeutics Stock Down 2.6%

Shares of NASDAQ GPCR opened at $21.79 on Monday. The firm’s 50-day simple moving average is $23.46 and its 200 day simple moving average is $24.04. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -25.05 and a beta of -1.87. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $47.48.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). On average, equities analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Mariner LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $665,000. Invesco Ltd. increased its stake in shares of Structure Therapeutics by 4.1% in the 4th quarter. Invesco Ltd. now owns 371,767 shares of the company’s stock valued at $10,082,000 after acquiring an additional 14,559 shares during the last quarter. Barclays PLC increased its stake in shares of Structure Therapeutics by 42.6% in the 4th quarter. Barclays PLC now owns 115,671 shares of the company’s stock valued at $3,138,000 after acquiring an additional 34,533 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Structure Therapeutics by 663.8% in the 1st quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock valued at $152,000 after acquiring an additional 7,627 shares during the last quarter. Finally, Foresite Capital Management VI LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $11,390,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.